Every year, scores of new, innovative and expensive prescription medications advance from the drug development pipeline into the marketplace. Which ones have the greatest potential to make a meaningful impact for patients and plan sponsors?  

On the latest episode of the Pharmacy Insights Podcast, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger dives into to the latest drug pipeline developments with Sara Guidry, Optum Rx Senior Director of Pipeline and Drug Surveillance and Arash Sadeghi, Optum Rx Clinical Pharmacist for Pipeline and Drug Surveillance. Touching on everything from cancer to Alzheimer’s, together they sift through the noise to identify the new drugs most likely to fill unmet medical needs and create potential financial implications for sponsors of the pharmacy benefit.